FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. 

Restricted - prescribing by consultant Ophthalmologists in-line with NICE TA's below.

Use biosimilar brand Yesafili® 1st line - Eylea® (originator brand) to be used for patients who cannot switch to biosimilar.

Entry reviewed: November 2025

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. 

Restricted - prescribing by consultant Ophthalmologists in-line with NICE TA's below.

FOR ALL PRESCRIBING - Blueteq or High Cost Drug form required - see link on Formulary Home page.

Restricted - prescribing by Consultant Ophthalmologists in line with the following NICE TA(s):

Approved for the treatment of retinopathy of prematurity.

FOR ALL PRESCRIBING - Blueteq or High Cost Drug form required - see link on Formulary Home page.

Restricted - prescribing by Consultatnt Ophthalmologist in line with the following NICE TA(s)

120 mg/mL solution for injection

120 mg/mL solution for injection in prefilled syringe

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. 

Restricted - prescribing by consultant Ophthalmologists in accordance with the following NICE TAs:

Biosimilar brand(s): Ongavia®, Ximluci® (preferred)

Originator brand: Lucentis®

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted - prescribing by consultant Ophthalmologists:

1. For the treatment of age related macular degeneration in accordance with NICE TA155.
2. For treating diabetic macular oedema in accordance with NICE TA274.

3. For Central Retinal Vein Occlusion in accordance with NICE TA283

4. For treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia in accordance with NICE TA 298.

Entry reviewed: November 2023